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Calsequestrin interacts directly with the cardiac ryanodine
receptor luminal domain
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ABSTRACT
Cardiac muscle contraction requires sarcoplasmic reticulum (SR)
Ca2+ release mediated by the quaternary complex comprising the
ryanodine receptor 2 (RyR2), calsequestrin 2 (CSQ2), junctin (encoded
by ASPH) and triadin. Here, we demonstrate that a direct interaction
exists between RyR2 and CSQ2. Topologically, CSQ2 binding occurs
at the first luminal loop of RyR2. Co-expression of RyR2 and CSQ2 in
a human cell line devoid of the other quaternary complex proteins
results in altered Ca2+-release dynamics compared to cells expressing
RyR2 only. These findings provide a new perspective for understanding
the SR luminal Ca2+ sensor and its involvement in cardiac physiology
and disease.
KEY WORDS: Ca2+ intracellular release, Calsequestrin, Excitation-
contraction coupling, Luminal Ca2+ sensor, Protein–protein
interaction, Ryanodine receptor, Sarcoplasmic reticulum
INTRODUCTION
Cardiac excitation–contraction coupling, where an action potential
elicits cardiomyocyte contraction, is mediated by ‘Ca2+-induced
Ca2+ release’. Upon plasma membrane depolarisation, Ca2+ influx
through voltage-gated Ca2+ channels triggers Ca2+ release through
the sarcoplasmic reticulum (SR)-located RyR2 to increase
cytoplasmic Ca2+ concentration and transduce sarcomere
contraction (Bers, 2002). Termination of SR Ca2+ release is an
incompletely understood process but appears to involve intra-SR
luminal Ca2+ regulation of RyR2 channel activity (Radwański et al.,
2013; Terentyev et al., 2002). Luminal Ca2+ exerts its effects
directly on RyR2 (Chen et al., 2014) and through the cardiac SR
Ca2+-binding protein CSQ2 (Beard et al., 2009; Gaburjakova et al.,
2013; Gyorke and Terentyev, 2008). Abnormal RyR2 regulation by
luminal Ca2+ causes diastolic SR Ca2+ leak, resulting in arrhythmias
and heart failure (Gyorke and Terentyev, 2008; Priori and Chen,
2011). Catecholaminergic polymorphic ventricular tachycardia
(CPVT) is an outstanding example of how arrhythmia induces
sudden cardiac death by perturbing Ca2+ handling (Cerrone et al.,
2009). CPVT type 1 is linked to RyR2 mutations inherited in an
autosomal-dominant manner, whereas CPVT type 2 is linked to
both dominant and recessive mutations of calsequestrin 2 (CSQ2)
(http://triad.fsm.it/cardmoc/).
RyR2 exists as a macromolecular complex composed of CSQ2
and the SR integral membrane proteins triadin and junctin (encoded
by ASPH), which together form the luminal Ca2+ sensor (Zhang
et al., 1997). CSQ2 interacts directly with both triadin and junctin in
a Ca2+-dependent manner, with 1–5 mM Ca2+ inhibiting these
interactions (Shin et al., 2000; Zhang et al., 1997). Their binding
sites have been mapped to the Asp-rich region at the C-terminus of
CSQ2 and to the KEKE motif (residues 200–224) of triadin
(Kobayashi et al., 2000; Shin et al., 2000). Triadin and junctin
interactions with RyR1 and RyR2 are also known to be direct, with
the RyR2–junctin interaction being Ca2+-independent (Guo and
Campbell, 1995; Zhang et al., 1997). The triadin KEKE motif
interacts with negatively charged residues within the second luminal
loop of RyR1 (Goonasekera et al., 2007; Lee et al., 2004), whereas
junctin association with the RyR1 or RyR2 involves both luminal
and cytoplasmic sites (Altschafl et al., 2011; Li et al., 2015).
Evidence for direct RyR–CSQ association is very scarce. Interaction
of calsequestrin 1 (CSQ1) with purified native skeletal muscle
RyR1 has been reported (Herzog et al., 2000), which could have
differential effects on channel activity depending on the presence of
triadin and/or junctin (Beard et al., 2002; Szegedi et al., 1999). To
our knowledge, there is no biochemical data for direct physical
association between RyR2 and CSQ2 in the heart. Thus, although
the functional association of RyR2 and CSQ2 is well established,
this is generally believed to be indirectly mediated through triadin
and junctin interactions (Beard et al., 2009; Gaburjakova et al.,
2013; Gyorke and Terentyev, 2008).
RESULTS AND DISCUSSION
Direct association of calsequestrin 2 with RyR2
Initially, we investigated the native RyR2 interaction with
recombinant purified CSQ2 using GST pull-down assays. GST
alone was used as negative control and GST–FKBP12.6 (also
known as FKBP1B) was used as a positive control. Purified (1 µM)
GST-fusion protein was incubated with CHAPS-solubilised RyR2
from pig cardiac SR and isolated with glutathione Sepharose
(Fig. 1A, bottom); the presence of co-precipitated RyR2 was
analysed by immunoblotting using Ab1093 (Fig. 1A, top). RyR2 was
efficiently co-precipitated by GST–CSQ2 and GST–FKBP12.6 but
not by GST alone. The interaction of recombinant GST–CSQ2 with
pig cardiac RyR2 might be direct or be mediated through the native-
RyR2-associated proteins triadin, junctin and calsequestrin 2. To
exclude an indirect interaction, we used recombinant human RyR2
expressed in HEK293 cells – a non-cardiac cell line lacking
endogenous junctin, triadin and CSQ2, as revealed by immunoblot
analysis (Fig. S1). Using GST pull-down assays, we found strong
GST–CSQ2 binding to recombinant human RyR2 (Fig. 1B),
indicating that triadin and junctin are non-essential for theReceived 3 May 2016; Accepted 5 September 2016
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RyR2–CSQ2 association. These experiments made use of purified
CSQ2 expressed in bacteria that lack the machinery for
glycosylation and phosphorylation, which are potential post-
translational modifications for native calsequestrin 2. We therefore
assessed the RyR2–CSQ2 interaction by performing co-
immunoprecipitation assays following their co-expression in
mammalian HEK293 cells. Hemagglutinin (HA)-tagged CSQ2
was immunoprecipitated with an antibody against HA from
CHAPS-solubilised HEK293 cell lysates (Fig. 1C, bottom), and
the presence of co-precipitated RyR2 was analysed by
immunoblotting using Ab1093 (Fig. 1C, top). RyR2 was recovered
from the anti-HA immunoprecipitate but not from the negative
control using non-immune rabbit IgG. In the reverse experiment,
immunoprecipitation of RyR2 with Ab1093 (Fig. S2, bottom)
resulted in co-precipitation of HA–CSQ2 (Fig. S2, top), providing
further evidence for direct complex formation between RyR2 and
CSQ2. Our findings are consistent with previous work that indicates
a physical association between the skeletal muscle isoforms, RyR1
and CSQ1, and that made use of purified native RyR1 with no
detectable levels of endogenous triadin or junctin (Beard et al.,
2002; Herzog et al., 2000; Szegedi et al., 1999).
CSQ2 interacts with the first luminal loop of RyR2
The direct interaction of CSQ2 can only occur with RyR2 peptide
sequences that face the SR lumen. To map the CSQ2-binding site,
we used four overlapping fragments covering the RyR2 C-terminus
containing all the transmembrane domains and intervening luminal
loops (BT constructs shown in Fig. 2A). HA–CSQ2, co-expressed
with Myc-tagged BT1D, BT1D2, BT1B2 and BT9 constructs (see
Fig. 2A) in HEK293 cells, was immunoprecipitated with an
antibody against HA from CHAPS-solubilised cell lysates (Fig. 2B,
bottom), and the presence of co-precipitated BT constructs was
analysed by immunoblotting using an antibody against Myc
(Fig. 2B, top). BT1D2 was the only RyR2 fragment recovered in
the anti-HA immunoprecipitate but not in the negative control using
non-immune rabbit IgG. The shorter BT1D construct that lacks the
first two transmembrane domains and intervening luminal loop was
found to be negative for an interaction with CSQ2. To further test
whether the CSQ2-binding site is contained within the RyR2 first
luminal loop (LL1), we generated the RyR2 LL1 fragment (residues
4521–4573) as a GST-fusion protein (GST-LL1) purified from
bacteria for use in pull-down assays; we were unable to use the LL1
construct in coimmunoprecipitation assays because it was expressed
Fig. 1. CSQ2 displays a direct interaction with RyR2. (A) GST pull-down experiments (n=3) of native RyR2 incubated with purified GST-fusion proteins as
indicated. Solubilised pig cardiac SR vesicles were incubated with purified GST-fusion proteins that had been captured on glutathione beads. Beads were
precipitated by centrifugation, and the presence of associated RyR2 was analysed by SDS-PAGE (4% gel) and immunoblotting using the Ab1093 antibody (top).
As negative control, pull-down assays were performed with GST alone. To detect the isolated GST-fusion proteins, one-tenth of pull-down samples was analysed
by SDS-PAGE (12% gel) and immunoblotting using an antibody against GST (AbGST, bottom). An aliquot of solubilised pig cardiac SRcorresponding to 1% (5 μg)
of the amount processed in the pull-down assay was also included in the gels. As a negative control, pulldown assays were performed with GST alone;
GST–FKBP12.6 was used as positive control for RyR2 interaction. (B) GST pull-down experiments (n=3) of recombinant human RyR2 incubated with purified
GST-fusion proteins as indicated. Solubilised HEK293 microsomes expressing RyR2 (HEKmicro) were incubated with purified GST-fusion proteins captured on
glutathione beads, and analysed as described in A above. (C) Co-immunoprecipitation (co-IP) analyses (n=3) of recombinant human RyR2 co-expressed with
CSQ2 in mammalian HEK293 cells. HA–CSQ2 was immunoprecipitated with an antibody against HA (AbHA) from solubilised HEK293 lysates, and the presence
of associated RyR2 was analysed by SDS-PAGE (4% gel) and immunoblotting using Ab1093 (top). As negative control, co-immunoprecipitation assays were
performed with non-immune rabbit IgG (Non-immune). To detect isolated HA–CSQ2, one-tenth of the immunoprecipitatewas analysed by SDS-PAGE (12% gel)
and western blotting (WB) using an antibody against HA (AbHA, bottom). An aliquot of HEK293 cell lysate corresponding to 1% (20 μg) of the amount processed in
the co-immunoprecipitation assay was also included in the gels.
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Fig. 2. Mapping the CSQ2-interacting site on RyR2. (A) Human RyR2 SR membrane topology (right) and diagram of overlapping BT1D, BT1D2, BT1B2 and
BT9 constructs covering the RyR2 C-terminus containing all the transmembrane domains and intervening luminal loops. M indicates membrane-spanning
domains. (B) Co-immunoprecipitation (co-IP) experiments (n=4) of recombinant human RyR2 fragments co-expressed with CSQ2 in HEK293 cells. HA–CSQ2
was immunoprecipitated with an antibody against HA (AbHA) from solubilised HEK293 lysates that co-expressed Myc-tagged BT constructs. As negative control,
co-immunoprecipitation assays were performed with non-immune rabbit IgG (non-immune). Immunoprecipitated proteins were resolved in separate SDS-PAGE
gels (12% for BT1D and BT1D2, 15% for BT1B2 and BT9, and 12% for HA–CSQ2) loaded with nine-tenths or one-tenth of the immunoprecipitates and were
analysed by immunoblotting using antibodies against Myc (AbcMyc, top) or HA (AbHA, bottom), respectively. An aliquot of HEK293 cell lysate corresponding to 1%
(20 μg) of the amount processed in the co-immunoprecipitation assay was also included in the gels. (C) GST pull-down experiments (n=4) of recombinant human
CSQ2 incubated with purified GST–LL1 (RyR2 residues 4521–4573) or GST alone serving as negative control. Solubilised HEK293 lysates expressing
HA–CSQ2were incubatedwith purified GST-fusion proteins captured on glutathione beads. Precipitated proteins were resolved in separate 12%SDS-PAGE gels
loaded with nine-tenths or one-tenth of the pull-down samples and were analysed by immunoblotting for HA (AbHA, top) or GST (AbGST, bottom), respectively.
(D) Competition binding experiments (n=3) to test the RyR2–CSQ2 interaction. HA–CSQ2 was immunoprecipitated with an antibody against HA (AbHA) from
solubilised HEK293 lysates co-expressing RyR2 in the presence of GST–LL1 or GST alone (negative control). Immunoprecipitated proteins were resolved in
separate 4% or 12%SDS-PAGE gels loaded with nine-tenths or one-tenth of the immunoprecipitates and were analysed by immunoblotting with Ab1093 (top) and
for HA (AbHA, bottom), respectively. (E) Co-immunoprecipitation experiments (n=4) of BT1D2 co-expressed with CSQ2 in HEK293 cells, performed under
different Ca2+ concentrations. HA–CSQ2 was immunoprecipitated with an antibody against HA (AbHA) from solubilised HEK293 lysates containing either 1 mM
EGTA, 100 µM CaCl2, 1 mM CaCl2 or 5 mM CaCl2, as indicated. The presence of co-precipitated BT1D2 was analysed by SDS-PAGE (10% gels) and
immunoblotting for Myc (AbcMyc, top) or HA (AbHA, bottom), respectively.
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very poorly in HEK293 cells. Purified (1 µM) GST-fusion protein
was incubated with CHAPS-solubilised HEK293 cell lysate
expressing HA–CSQ2 and isolated with glutathione Sepharose
(Fig. 2C, bottom); the presence of co-precipitated HA–CSQ2 was
analysed by immunoblotting using an antibody against HA
(Fig. 2C, top). HA–CSQ2 was efficiently pulled down by GST–
LL1, whereas binding to GST alone, serving as negative control,
was negligible. To further assess whether the CSQ2-binding site is
contained within the RyR2 first luminal loop, we conducted
competition binding experiments to test whether GST–LL1
disrupted the CSQ2 interaction with the full-length RyR2. RyR2
was co-expressed with HA–CSQ2 in HEK293 cells, and co-
immunoprecipitation assays were performed in the presence of
1 µM GST–LL1 or GST alone. As seen in Fig. 2D, in the presence
of GST alone, RyR2 was efficiently recovered in the anti-HA
immunoprecipitate, whereas the inclusion of GST–LL1 abolished
the RyR2 interaction with HA–CSQ2.
The experiments described above were conducted using assay
buffers containing residual, micromolar Ca2+. Further investigation
of the Ca2+ sensitivity of the RyR2–CSQ2 interaction was
performed in the presence of near-physiological SR Ca2+
concentrations (1 mM CaCl2), or in the absence of Ca2+ (1 mM
EGTA), as well as under conditions of high (5 mM CaCl2) or low
(100 µM CaCl2) SR Ca2+ load. Using co-immunoprecipitation
assays, we found comparable amounts of BT1D2 binding to
HA–CSQ2 in the presence of 1 mM EGTA, and 100 µM and 1 mM
CaCl2; however, recovery of BT1D2 in the anti-HA
immunoprecipitate was diminished with 5 mM CaCl2 (Fig. 2E).
Quantitative data (n=4) following densitometry analysis and
normalisation for the amount of protein expressed in the cell
lysate indicate equivalent amounts of HA–CSQ2 binding to BT1D2
for Ca2+ concentrations up to 1 mM (1 mM EGTA, 154.2±20.8;
100 µM CaCl2, 126.7±30.5; 1 mM CaCl2, 149.0±43.5; mean±
s.e.m.); however, 5 mM CaCl2 substantially reduced binding by
>50% (71.5±36.9, P<0.05 two-tailed paired Student’s t-test
compared to 1 mMCaCl2). These results suggest that at Ca
2+
levels within the physiological SR range (≤1 mM), the RyR2–
CSQ2 interaction remains intact but that it is diminished at supra-
millimolar Ca2+ levels, in agreement with previous reports (Beard
et al., 2009; Gaburjakova et al., 2013). Our data are also consistent
with recent single-channel recordings demonstrating that CSQ2
effects on RyR2 activity are unaffected by luminal Ca2+
concentration changes up to 1 mM (Chen et al., 2013; Tencerová
et al., 2012). CSQ2 undergoes structural changes upon Ca2+ binding
and polymerises at >1 mM Ca2+ concentrations; it is believed that a
front-to-front CSQ2 dimer is first formed, with these dimers
forming a back-to-back stack to produce a polymeric structure
(Gaburjakova et al., 2013). Our findings suggest that the RyR2-
interacting site on CSQ2 assumes a Ca2+-independent conformation
that might be obstructed if CSQ2 is in its polymeric form. They
further indicate that monomeric CSQ2 is sufficient for direct RyR2
interaction.
Direct CSQ2 association with RyR2 regulates cellular Ca2+-
release dynamics
Expression of RyR2 in HEK293 cells is known to result in
spontaneous global Ca2+-release events (Jiang et al., 2002; Seidel
et al., 2015). To assess the functional impact of CSQ2 on RyR2
in the absence of triadin and junctin, we generated HEK293 cells
that stably expressed CSQ2, verified by immunoblotting (Fig. S1).
Co-expression of RyR2 in the CSQ2-expressing stable cell line
resulted in an increase in the duration between Ca2+-release events
(inter-transient duration), decreasing their overall frequency
(Fig. 3A,F,G), compared to that in cells that expressed RyR2
alone. Rates of transient rise and decay were also slower (Fig. 3C,
D), lengthening the overall duration of Ca2+ release (Fig. 3E), with
no significant change in amplitude (Fig. 3B). These whole-cell
functional results provide further evidence for a direct RyR2–
CSQ2 interaction and corroborate our biochemical findings.
Notably, our results are consistent with the previously reported
inhibitory action of this luminal accessory protein in
cardiomyocytes, where CSQ2 would associate with RyR2 both
directly and indirectly through junctin and triadin. The decrease in
Ca2+-release event frequency (Fig. 3G) that we observed agrees
with that reported in most CSQ2-overexpression studies (Jones
et al., 1998; Sato et al., 1998; Terentyev et al., 2003; Wang et al.,
2000). The longer inter-transient duration (Fig. 3F) is also
consistent with the increase in Ca2+-binding sites within the
store provided by CSQ2, indicating that more time is required to
reach a high-enough level of free luminal Ca2+ to trigger the next
Ca2+-release event (Jiang et al., 2002). In addition, it has been
reported that although RyR2 activity decreases when CSQ2 is
dissociated (Wei et al., 2009), the relative open probability
increases more steeply with luminal Ca2+ after CSQ2 dissociation
(Dulhunty et al., 2012), in agreement with our findings that the
rate of spontaneous Ca2+ release is increased in the absence of
CSQ2 (Fig. 3C). Thus, although we cannot exclude the involvement
of junctin and triadin, our data obtained in a cell line devoid of
these accessory proteins suggest that the functional effects of
CSQ2 are mediated primarily through its direct structural interaction
with RyR2.
In conclusion, our data indicate a direct functional RyR2
interaction with CSQ2, shedding more light on the quaternary
structural assembly of the SR luminal Ca2+ sensor. Elucidation
of the CSQ2-binding site within the first luminal loop of RyR2
should help in further understanding the pathologic mechanism(s)
underlying arrhythmias and sudden cardiac death.
MATERIALS AND METHODS
Materials
Cell culture reagents and Fluo-3 AMwere obtained from Life Technologies,
electrophoresis equipment and reagents from Bio-Rad, protease inhibitor
cocktail (Complete) from Roche, CHAPS from Merck, nProtein-A
Sepharose and glutathione Sepharose 4B from GE Healthcare, secondary
antibodies from Santa Cruz Biotechnology, enhanced chemiluminescence
reagents from Pierce, DNA restriction endonucleases from New England
Biolabs, Pfu DNA polymerase from Promega, oligonucleotides and all
other reagents were from Sigma. Antibodies used for immunoprecipitation:
(1 μg) rabbit anti-HA antibody (Y-11, cat. no. sc-805, 1:40 dilution for
immunoprecipitation) and non-immune rabbit IgG were from Santa Cruz
Biotechnology. Antibodies used in immunoblotting were mouse anti-Myc
(9E10, cat. no. sc-40, 1:500 dilution for western blotting) from Santa Cruz
Biotechnology, mouse anti-HA (16B12, cat. no. MMS-101, 1:1000 dilution
forwestern blotting) fromCovance; rabbit anti-GST (1:2000) (Zissimopoulos
et al., 2012, 2006), and rabbit RyR2-specific (Ab1093, epitope at residues
4454-4474; 1:500) (Zissimopoulos et al., 2012, 2006) antibodies.
Plasmid construction
Human CSQ2 cDNA containing the entire open reading was generated by
performing PCR amplification from a human heart cDNA library (Clontech)
and was cloned into the bacterial expression vector pGEX6P1 (GE
Healthcare). For transient mammalian expression, CSQ2 cDNA was
subcloned into a modified pCR3 vector (Life Technologies) containing an
N-terminal HA peptide epitope tag, whereas for stable expression, it was
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cloned into pcDNA3.1(+)hygro (Life Technologies). Human RyR2
constructs were generated by performing PCR amplification [using
human (h)RyR2 cDNA as template] and cloning into a modified pCR3
vector containing an N-terminal Myc peptide epitope tag. For bacterial
expression of the LL1 construct, the cDNA was subcloned into the
pGEX6P1 vector. Oligonucleotide primers and restriction enzyme cloning
sites used are available upon request. All plasmids were verified by direct
DNA sequencing (BigDye, Perkin-Elmer).
Mammalian cell culture and transfection
HEK293 cells (ATCC®) were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 2 mM glutamine and 10% fetal bovine serum
under a humidified atmosphere of 5% CO2 at 37°C. On reaching ∼70%
confluence, cells growing on a 100-mm Petri dish were transiently
transfected with 24 μg of plasmid DNA using the calcium phosphate
precipitation method, as described elsewhere (Stanczyk et al., 2016).
Cells were collected 24 h post-transfection and stored at−80°C. Transfected
cells were also used to generate a clonally-derived CSQ2 stable cell line
using limiting dilution with selection using hygromycin (400 µg ml−1). For
Ca2+ imaging, stable cells from this clonal population were transiently
transfected with eGFP–hRyR2 using Effectene® (Qiagen) according to the
manufacturer’s instructions.
Single cell Ca2+-imaging
Cells stably expressing CSQ2 (∼1×105) were seeded onto poly-lysine-
coated glass-bottomed dishes (MatTek™) before transient transfection
with eGFP–hRyR2. After 48 h, cells were loaded with Fluo-3 AM (10 µM)
for 45 min at 30°C. Following de-esterification, cells were immersed in
Krebs-Ringer-Hepes buffer for imaging (120 mM NaCl, 5.5 mM glucose,
25 mM Hepes, 4.8 mM KCl, 1.2 mM KH2PO4, 1.2 mM MgSO4, 1.3 mM
CaCl2, pH 7.4). RyR2-mediated spontaneous Ca2+-release events were
monitored using a laser scanning confocal microscope (Leica SP5) with an
oil immersion 63× objective lens with excitation at 488 nm, and Ca2+-
dependent fluorescence emission was detected over a 520±28 nm range. Using
LeicaMicrosystems software (LAS-AF), Ca2+-release events were recorded for
2 min (five frames per second) at 512×512 pixel resolution, and acquired
regions of interest representing global Ca2+ environments (typically ∼50 μm2)
were selected. Amplitude and temporal characteristics of spontaneous Ca2+
release were quantified and are displayed as means±s.e.m. Statistical analysis
was performed using unpaired Student’s t-test.
Other methods
Bacterial expression and purification of GST-fusion proteins, GST
pull-down and co-immunoprecipitation assays, SR preparation and
immunoblotting were performed as described previously (Stanczyk et al.,
2016; Zissimopoulos et al., 2012, 2006). Densitometry analysis was
performed using a GS-700 scanner (Bio-Rad) and Quantity One software
(Bio-Rad); data are expressed as means±s.e.m. and statistical analysis was
performed using paired Student’s t-test.
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